2013³â 11¿ù 10ÀÏ~13ÀϱîÁö ÀϺ» ¿À»çÄ«, ¿À»çÄ«±¹Á¦È¸ÀÇÀå¿¡¼ Á¦12Â÷ ±¹Á¦ÀÌÁ¾À̽ÄÇÐȸ Çмú´ëȸ°¡ ¼ºÈ²¸® °³ÃֵǾú´Ù.
Âü°¡ÀÚµéÀº Àü¼¼°è¸¦ Æ÷ÇÔÇÏ¿© ¹Ì±¹, À¯·´, È£ÁÖ, ´ºÁú¶õµå, Áß±¹, ÀϺ», Çѱ¹µî¿¡¼ ¾à 400 ¿©¸íÀÇ ÀÌÁ¾À̽Ŀ¬±¸ °ü·ÃÇÐÀÚµéÀÌ 4ÀÏ°£
400 ¿©ÆíÀÇ ÀÌÁ¾À̽İü·Ã ¿¬±¸¹ßÇ¥¿Í Ư°, ½ÉÆ÷Áö¿òµîÀ¸·Î ¿¶í Çмú´ëȸ°¡ ÁøÇàµÇ¾ú´Ù.
Çѱ¹¿¡¼µµ ¿©·¯´ëÇп¡¼ ¸¹Àº ¿¬±¸ÁøÀÌ Âü¼®ÇÏ¿´À¸¸ç ÃÊû°¿¬, ¿¬±¸¹ßÇ¥¸¦ ½ÃÇàÇÏ¿´´Ù. ƯÈ÷ ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¿¬±¸ÁøÀÌ Çѱ¹ ´ëÇ¥µéÀÇ
ÁÖ·ù¸¦ ÀÌ·ç°í ÃÊû°ÀÇ, ÁÂÀå, ½Ê¿©ÆíÀÇ ¿¬±¸°á°ú¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ¼¿ï´ëÇб³º´¿ø ÈäºÎ¿Ü°ú¿¡¼µµ Development of novel
combined anticalcification protocol including immunologic modification for
prolonged durability of cardiac xenograft in animal study¿Í In-vivo efficacy for
treatment with decellularization, alpha-galactosidase, spacefiller, organic
solvent and detoxifixation of GA-fixed cardiac xenograft using alpha-gal mouse
implantation model À̶õ ¿¬Á¦¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ±Ý³â¿¡´Â alpha-gal KO pig¿¡ genetic modification ÁøÇàÀÌ
´õ¿í ÇöÀúÇÏ°í, genetically induced disease(agenesis) model°³¹ß, chimerism ¹æ¹ýµµ ´«ºÎ½Ã°Ô
¹ßÀüµÇ¾ú´Ù. Çѱ¹µµ ÀÌ·¯ÇÑ ÀÌÁ¾À̽Ŀ¡¼ À¯ÀüÀÚ Ã³¸® ±â¼úµéÀÌ »¡¸® Çâ»óµÇ±æ ±â¿øÇÑ´Ù.
|